MedDataX Logo

Interleukin23 in Systemic Lupus

NCT ID: NCT06713187

Last Updated: 2024-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-01

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

for all patients detailed history taken clinical and rhumatological examination will be assessed and SLEDAI score will be collected from the case record of the patients\&laboratory investigation included 1\_erythrocytic sedimentation rate.2\_complete blood count.3\_interleukin23 .4\_complement 3\&4.5\_Antinuclear Antibodies.6\_Anti double stranded antibodies.7\_full basic biochemical test(24 urine protien)8\_high resolution computed tomography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus Related Interstial Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1

Patients with systemic lupus erythematosus without interstial lung disease.

Group Type ACTIVE_COMPARATOR

interleukin 23

Intervention Type BIOLOGICAL

assessment of interleukin 23 in Sera of patients using ELIZA

group2

Patients with systemic lupus erythematosus with interstial lung disease.

Group Type ACTIVE_COMPARATOR

interleukin 23

Intervention Type BIOLOGICAL

assessment of interleukin 23 in Sera of patients using ELIZA

group3

healthy control groups

Group Type ACTIVE_COMPARATOR

interleukin 23

Intervention Type BIOLOGICAL

assessment of interleukin 23 in Sera of patients using ELIZA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

interleukin 23

assessment of interleukin 23 in Sera of patients using ELIZA

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.

Exclusion Criteria

* patients with chest conditions rather than interstial lung disease \&who receiving biological blocking antibodies\& those treated with immunosuppressive drugs.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

khadiga Mahmoud Salem

resident doctor at clinical pathology department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag university hospital

Sohag, , Egypt

Site Status RECRUITING

Sohag university

Sohag, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Khadiga M Salem, resident doctor

Role: CONTACT

[email protected]
01069152448

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Magdy M Ameen, Professor

Role: primary

Magdy M Ameen, Professor

Role: primary

[email protected]
0934602963

References

Explore related publications, articles, or registry entries linked to this study.

Yap DY, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol. 2010;2010:365083. doi: 10.1155/2010/365083. Epub 2010 May 6.

Reference Type BACKGROUND
PMID: 20467470 (View on PubMed)

Haroon MM, Hegazy GA, Hassanien MA, Shaker O, Hussein WH. Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices. Biologics. 2023 Jan 18;17:1-9. doi: 10.2147/BTT.S389021. eCollection 2023.

Reference Type BACKGROUND
PMID: 36698375 (View on PubMed)

Sisto M, Lisi S. Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries. J Clin Med. 2023 Sep 1;12(17):5699. doi: 10.3390/jcm12175699.

Reference Type BACKGROUND
PMID: 37685766 (View on PubMed)

Senoo S, Taniguchi A, Itano J, Oda N, Morichika D, Fujii U, Guo L, Sunami R, Kanehiro A, Tokioka F, Yoshimura A, Kiura K, Maeda Y, Miyahara N. Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2021 Nov 1;321(5):L925-L940. doi: 10.1152/ajplung.00582.2020. Epub 2021 Sep 15.

Reference Type BACKGROUND
PMID: 34524907 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh_Med__24_11_09MS

Identifier Type: -

Identifier Source: org_study_id